Ocaliva, a synthetic bile acid analog with high affinity for the nuclear bile acid receptor FXR, is effective in treating primary biliary cholangitis, an autoimmune liver disease. It works in patients who fail to respond to or cannot tolerate conventional treatment with the natural bile acid ursodeoxycholic acid (UDCA). 
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EFFECTS ON TARGETS
Ocaliva activates FXR directly in the liver and increases FGF19 hormone levels via intestinal FXR activation. In hepatocytes, FGF19 signaling through FGFR4/β-Klotho and FXR decrease toxic accumulation of bile acids by increasing their export, minimizing their uptake, and reducing their synthesis, resulting in decreased inflammatory and fibrotic gene expression.
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